Aktien Sensor

Genmab’s stock price has taken a hit due to market volatility, raising concerns about the company’s reliance on antibody therapeutics and lack of diversification.

Eurofins Scientific SE has reported strong first half 2025 results, driven by growth in the healthcare sector, and reaffirmed its ambitious objectives for 2025 and 2027.

BioMarin Pharmaceutical Inc.’s stock has declined by nearly 60% over the past decade, but analysts consider it a ‘Strong Buy’ due to its undervalued status.

Galderma’s first-half performance has shattered records, driven by double-digit growth in international markets and a diversified product portfolio, solidifying its position as a leader in the dermatology space.

CSL, an Australian biotech firm, has received FDA approval for its ANDEMBRY treatment, a therapy for hereditary angioedema in patients aged 12 and above.

Takeda Pharmaceutical’s share price has demonstrated remarkable stability over the past 52 weeks, driven by the company’s solid financial foundation and strategic decision-making.

The Shanghai Fosun Pharmaceutical Group Co Ltd has seen a significant surge in its stock price due to a combination of new policies, regional success stories, and operational strengths.

Argenx SE is set to report its half-year 2025 financial results on July 31, 2025, as the biotech sector experiences positive trends despite the company’s relatively stable stock price.

Illumina Inc’s stock price has surged after Cathie Wood’s ARK Invest made a $3 million purchase of shares, sparking optimism about the company’s long-term prospects in precision medicine and gene sequencing.

Regeneron Pharmaceuticals Inc.’s stock price has surged in recent days due to positive market sentiment and breakthroughs in its research, driven by the company’s growing influence and success in the biotechnology industry.